HBIO
Harvard Bioscience Inc
NASDAQ: HBIO · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$6.38
+4.08% today
Updated 2026-04-30
Market cap
$30.80M
P/E ratio
—
P/S ratio
0.36x
EPS (TTM)
$-12.80
Dividend yield
—
52W range
$3 – $9
Volume
0.2M
Harvard Bioscience Inc (HBIO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-65.50%
Operating margin
14.00%
ROE
-147.10%
ROA
0.91%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $76.18M | $-2.34M | 50.00% | 11.41% | -3.07% |
| 2007 | $83.41M | $-1.35M | 48.25% | 11.43% | -1.62% |
| 2008 | $88.05M | $1.67M | 47.88% | 9.63% | 1.90% |
| 2009 | $85.77M | $7.23M | 48.60% | 9.39% | 8.43% |
| 2010 | $108.18M | $19.02M | 47.86% | 9.45% | 17.58% |
| 2011 | $108.86M | $3.81M | 46.17% | 5.58% | 3.50% |
| 2012 | $111.17M | $2.37M | 47.15% | 2.85% | 2.13% |
| 2013 | $105.17M | $-1.83M | 45.35% | 1.46% | -1.74% |
| 2014 | $108.66M | $2.35M | 45.41% | 6.09% | 2.17% |
| 2015 | $108.66M | $-19.04M | 44.84% | -1.58% | -17.52% |
| 2016 | $104.52M | $-4.31M | 46.32% | -2.87% | -4.12% |
| 2017 | $101.88M | $-865000.00 | 46.72% | -0.10% | -0.85% |
| 2018 | $120.77M | $-3.46M | 52.31% | 0.81% | -2.87% |
| 2019 | $116.18M | $-4.69M | 55.37% | 0.32% | -4.03% |
| 2020 | $102.10M | $-7.81M | 56.85% | 0.22% | -7.65% |
| 2021 | $118.90M | $-288000.00 | 56.90% | 1.74% | -0.24% |
| 2022 | $113.33M | $-9.52M | 53.66% | -6.12% | -8.40% |
| 2023 | $112.25M | $-3.42M | 58.86% | 1.69% | -3.04% |
| 2024 | $94.14M | $-12.40M | 58.18% | -6.60% | -13.18% |
| 2025 | $86.55M | $-56.70M | 53.01% | -0.73% | -65.51% |